




DRIVE Annual Forum is a unique opportunity to engage with DRIVE associate partners, collaborators and stakeholders





“Brand-specific influenza vaccine effectiveness and COVID-19 impact: how to be better prepared for the 2020/21 season”



DRIVE ANNUAL FORUM WEBINARS 2020

September 22 & September 24, 2020
A Virtual Meeting



DAY 1 – TUESDAY, SEPTEMBER 22, 2020: 3 pm to 5:30 pm CET

“2019/20 Season: Brand Specific Influenza Vaccine Effectiveness and COVID-19

Impact: How to be Better Prepared for the Next Season 2020/2021”

15:00-15:20	Welcome and agenda (1) 2019/20 season: DRIVE achievements and lessons learnt	(10)(2e)
15:20-15:45	2019/20 season: DRIVE sites experience with COVID-19 pandemic and study management (2) Q&A session: 10 minutes	(10)(2e)
15:45-16:35	2019/20 season: DRIVE Brand-specific influenza vaccine effectiveness results and COVID-19 impact (3) Q&A session: 20 minutes	(10)(2e) (10)(2e) (10)(2a)
16:35-16:55	ECDC management of COVID-19 surveillance in EU: impact on influenza surveillance and status update (4) Q&A session: 10 minutes	(10)(2e)
16:55-17:20	2020/21 season: DRIVE study platform scale-up and adaptation for COVID-19 (5) Q&A session: 15 minutes	(10)(2e) (10)(2e)
17:20-17:30	Closure and Announcement of next Webinar (6)	



“Building on existing influenza infrastructure to monitor and evaluate future COVID-19 vaccines”



DRIVE ANNUAL FORUM WEBINARS 2020

September 22 & September 24, 2020
A Virtual Meeting



DAY 2 – THURSDAY, SEPTEMBER 24, 2020: 3 pm to 5:15 pm CET

“Building on existing influenza infrastructure to monitor and evaluate future COVID-19 vaccines”

15:00-15:10	Welcome, agenda and brief summary of previous webinar (7)	
15:10-15:30	EMA Expectations for an EU Post-Marketing Platform for Vaccines Effectiveness Evaluation (8) Q&A session: 10 minutes	
15:30-15:50	ACCESS Project Update and DRIVE Contribution (9) Q&A session: 10 minutes	(10)(2e) (10)(2e) (10)(2e)
15:50-16:10	FDA views on RWE on Vaccine Effectiveness (10) Q&A session: 10 minutes	(10)(2a)
16:10-16:40	DRIVE assets for the future Public-private collaboration, COVID-19 brand specific vaccines effectiveness & Open data strategy (11) Impact of joint influenza/COVID-19 vaccination on the vaccine effectiveness estimates from TND studies (12) Joint Q&A session: 10 minutes	(10)(2e) (10)(2e) (10)(2e)
16:40-17:10	Roundtable session (13) (10)(2e) (10)(2e) (10)(2e) (10)(2e) (THL)	
17:10-17:15	Closing Remarks (14)	

www.drive-eu.org



The DRIVE Project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777363. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation and EFPIA